List of works - Jayesh Desai

31st Annual Meeting and Associated Programs of the Society for Immunotherapy of Cancer (SITC 2016): part one

scientific article (publication date: November 2016)

A First-Time-In-Human Phase I Clinical Trial of Bispecific Antibody-Targeted, Paclitaxel-Packaged Bacterial Minicells

scientific article published on 11 December 2015

A Phase Ib Dose-Escalation and Expansion Study of the BCL2 Inhibitor Venetoclax Combined with Tamoxifen in ER and BCL2-Positive Metastatic Breast Cancer

scientific article published on 05 December 2018

A multi-arm phase I dose escalating study of an oral NOTCH inhibitor BMS-986115 in patients with advanced solid tumours.

scientific article published on 10 April 2018

A mutant BRAF V600E-specific immunohistochemical assay: correlation with molecular mutation status and clinical outcome in colorectal cancer

scientific article

A phase 1, first-in-human study of AMG 900, an orally administered pan-Aurora kinase inhibitor, in adult patients with advanced solid tumors

scientific article published on 07 July 2018

A phase I trial to determine safety and pharmacokinetics of ASLAN002, an oral MET superfamily kinase inhibitor, in patients with advanced or metastatic solid cancers.

scientific article

A phase Ib/II translational study of sunitinib with neoadjuvant radiotherapy in soft-tissue sarcoma

scientific article

An Australasian perspective on sarcoma research, translational biology and clinical trials: the Australasian Sarcoma Study Group (ASSG).

scientific article published on February 2014

An initial watch and wait approach is a valid strategy for selected patients with newly diagnosed metastatic colorectal cancer.

scientific article published on 24 June 2012

Analysis of cellular phosphatidylinositol (3,4,5)-trisphosphate levels and distribution using confocal fluorescent microscopy

scientific article published on 25 June 2010

Analysis of local chronic inflammatory cell infiltrate combined with systemic inflammation improves prognostication in stage II colon cancer independent of standard clinicopathologic criteria

scientific article published on 13 August 2015

Antiangiogenic therapies targeting the vascular endothelia growth factor signaling system.

scientific article published on January 2012

Binimetinib, Encorafenib, and Cetuximab Triplet Therapy for Patients With BRAF V600E-Mutant Metastatic Colorectal Cancer: Safety Lead-In Results From the Phase III BEACON Colorectal Cancer Study

scientific article published on 20 March 2019

Blood-based biomarkers of SU11248 activity and clinical outcome in patients with metastatic imatinib-resistant gastrointestinal stromal tumor.

scientific article published on May 2007

CART-WHEEL.org: An Ethically Approved Online Database for Patient-Entered Data to Facilitate Rare Cancer Research

scientific article published on 01 February 2020

Cetuximab Alone or With Irinotecan for Resistant KRAS-, NRAS-, BRAF- and PIK3CA-wild-type Metastatic Colorectal Cancer: The AGITG Randomized Phase II ICECREAM Study

scientific article published on 08 June 2018

Circulating tumor DNA analysis detects minimal residual disease and predicts recurrence in patients with stage II colon cancer

scientific article

Circulating tumor DNA as an early marker of therapeutic response in patients with metastatic colorectal cancer

scientific article published on 7 April 2015

Clinical, pharmacodynamic, and pharmacokinetic evaluation of BNC105P: a phase I trial of a novel vascular disrupting agent and inhibitor of cancer cell proliferation.

scientific article published on 20 June 2011

Clonal evolution of resistance to imatinib in patients with metastatic gastrointestinal stromal tumors

scientific article published on 01 September 2007

Comprehensive mapping of p53 pathway alterations reveals an apparent role for both SNP309 and MDM2 amplification in sarcomagenesis

scientific article published on 15 December 2010

Controversies in the management of gastrointestinal stromal tumors

scientific article published on 27 March 2014

Cost-effectiveness analysis of imaging surveillance in stage II and III extremity soft tissue sarcoma: an Australian perspective

scientific article published on 03 February 2020

Criteria-based curation of a therapy-focused compendium to support treatment recommendations in precision oncology

scientific article published on 23 June 2021

DNA copy-number alterations underlie gene expression differences between microsatellite stable and unstable colorectal cancers

scientific article published on December 2008

Developing a national database for metastatic colorectal cancer management: perspectives and challenges.

scientific article published in November 2013

Different APC genotypes in proximal and distal sporadic colorectal cancers suggest distinct WNT/β-catenin signalling thresholds for tumourigenesis.

scientific article published on 22 October 2012

Dose optimization of tyrosine kinase inhibitors to improve outcomes in GIST ⬇️

scientific article published on February 20, 2012

Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial

scientific article

Encorafenib, Binimetinib, and Cetuximab in BRAF V600E-Mutated Colorectal Cancer

scientific article published on 30 September 2019

Examining the impact of regular aspirin use and PIK3CA mutations on survival in stage 2 colon cancer

scientific article published on November 2016

Exploring the feasibility and utility of exome-scale tumour sequencing in a clinical setting

scientific article published on 01 July 2018

First-in-Man Dose-Escalation Study of the Selective BRAF Inhibitor RG7256 in Patients with BRAF V600-Mutated Advanced Solid Tumors.

scientific article published on 27 August 2015

First-in-human phase I clinical trial of a combined immune modulatory approach using TetMYB vaccine and Anti-PD-1 antibody in patients with advanced solid cancer including colorectal or adenoid cystic carcinoma: The MYPHISMO study protocol (NCT03287

scientific article published on 10 July 2019

Gemcitabine and vinorelbine combination chemotherapy for patients with advanced soft tissue sarcomas: results of a phase II trial.

scientific article

Gender-specific activity of chemotherapy correlates with outcomes in chemosensitive cancers of young adulthood.

scientific article

Girdin (GIV) Expression as a Prognostic Marker of Recurrence in Mismatch Repair-Proficient Stage II Colon Cancer

scientific article published on 30 March 2016

Histone deacetylase inhibitors in cancer: what have we learned?

scientific article published on 23 December 2014

Hypothyroidism after sunitinib treatment for patients with gastrointestinal stromal tumors.

scientific article

ICECREAM: randomised phase II study of cetuximab alone or in combination with irinotecan in patients with metastatic colorectal cancer with either KRAS, NRAS, BRAF and PI3KCA wild type, or G13D mutated tumours

scientific article

Immunomodulation by MYB is associated with tumor relapse in patients with early stage colorectal cancer.

scientific article published on 29 June 2016

Impact of BRAF mutation and microsatellite instability on the pattern of metastatic spread and prognosis in metastatic colorectal cancer

scientific article

Impact of Diabetes Status and Medication on Presentation, Treatment, and Outcome of Stage II Colon Cancer Patients

scientific article published on 5 May 2015

Impact of Primary Tumor Site on Bevacizumab Efficacy in Metastatic Colorectal Cancer

scientific article published on 13 February 2016

Impact of body mass index on colorectal cancer treatment and outcomes: need for prospective and comprehensive data.

scientific article published on 17 February 2009

Impact of regular aspirin use on overall and cancer-specific survival in patients with colorectal cancer harboring a PIK3CA mutation

scientific article published on 31 December 2014

KRAS Mutation Is Associated with Lung Metastasis in Patients with Curatively Resected Colorectal Cancer

scientific article published on 14 January 2011

KRAS mutation testing of metastatic colorectal cancer in Australia: where are we at?

scientific article published on 09 May 2014

KRASG12C Inhibition with Sotorasib in Advanced Solid Tumors

scientific article published on 20 September 2020

Lack of clinical activity with crizotinib in a patient with FUS rearranged rhabdomyosarcoma with ALK protein overexpression

scientific article published on 27 August 2019

Long-term efficacy of imatinib mesylate in patients with advanced Tenosynovial Giant Cell Tumor

scientific article published on 10 October 2019

MACROD2 Haploinsufficiency Impairs Catalytic Activity of PARP1 and Promotes Chromosome Instability and Growth of Intestinal Tumors

scientific article published on 07 June 2018

Management of gastrointestinal stromal tumors in the era of tyrosine kinase inhibitors.

scientific article

Mechanistic Insights of an Immunological Adverse Event Induced by an Anti-KIT Antibody Drug Conjugate and Mitigation Strategies

scientific article published on 03 April 2018

Metastasis-Associated Gene Expression Changes Predict Poor Outcomes in Patients with Dukes Stage B and C Colorectal Cancer

scientific article

Microsatellite instability status is critical to analysis of survival in stage II colon cancer

scientific article published on 09 January 2012

Multicenter retrospective analysis of metastatic colorectal cancer (CRC) with high-level microsatellite instability (MSI-H).

scientific article

Neurofibromatosis type 1-associated wild-type gastrointestinal stromal tumor treated with anti-IGF-1R monoclonal antibody.

scientific article

Nivolumab for the treatment of colorectal cancer

scientific article published on 11 June 2018

Nivolumab in patients with metastatic DNA mismatch repair-deficient or microsatellite instability-high colorectal cancer (CheckMate 142): an open-label, multicentre, phase 2 study.

scientific article published on 19 July 2017

Novel Vaccine Targeting Colonic Adenoma: a Pre-clinical Model

scientific article published on 08 January 2019

Novel quality indicators for metastatic colorectal cancer management identify significant variations in these measures across treatment centers in Australia.

scientific article

Nutlin-3a efficacy in sarcoma predicted by transcriptomic and epigenetic profiling

scientific article published on 13 December 2013

Optimising the management of soft tissue tumours ⬇️

scientific article published on June 1, 2011

Overview of biomarkers in metastatic colorectal cancer: tumour, blood and patient-related factors.

scientific article published on 02 July 2012

PIK3CA and PTEN gene and exon mutation-specific clinicopathologic and molecular associations in colorectal cancer

scientific article published on 30 April 2013

Pexidartinib versus placebo for advanced tenosynovial giant cell tumour (ENLIVEN): a randomised phase 3 trial

scientific article published on 19 June 2019

Phase I, Open-Label, Dose-Escalation/Dose-Expansion Study of Lifirafenib (BGB-283), an RAF Family Kinase Inhibitor, in Patients With Solid Tumors

scientific article published on 17 March 2020

Phase II study of ganitumab, a fully human anti-type-1 insulin-like growth factor receptor antibody, in patients with metastatic Ewing family tumors or desmoplastic small round cell tumors

scientific article

Phase Ib study of atezolizumab combined with cobimetinib in patients with solid tumors

scientific article published on 01 July 2019

Precision oncology using a clinician-directed, tailored approach to molecular profiling.

scientific article published on 30 October 2017

Primary Tumor Resection in Patients With Metastatic Colorectal Cancer Is Associated With Reversal of Systemic Inflammation and Improved Survival.

scientific article

Profound MEK inhibitor response in a cutaneous melanoma harboring a GOLGA4-RAF1 fusion

scientific article published on 05 March 2019

Re: Residual treatment disparities after oncology referral for rectal cancer

scientific article published on 25 November 2008

Recurrent SPECC1L-NTRK fusions in paediatric sarcoma and brain tumours

scientific article published on 03 November 2020

Resistance to BRAF Inhibition in BRAF-Mutant Colon Cancer Can Be Overcome with PI3K Inhibition or Demethylating Agents ⬇️

scientific article published on December 18, 2012

Response assessment in gastrointestinal stromal tumor.

scientific article published on 07 January 2011

Response to "Disparities in the use of chemotherapy and monoclonal antibody therapy for elderly advanced colorectal cancer patients in the community oncology setting".

scientific article published in January 2009

Response to Cetuximab With or Without Irinotecan in Patients With Refractory Metastatic Colorectal Cancer Harboring the KRAS G13D Mutation: Australasian Gastro-Intestinal Trials Group ICECREAM Study

scientific article

SMAD2, SMAD3 and SMAD4 mutations in colorectal cancer

scientific article

Safety and pharmacokinetics of motesanib in combination with gemcitabine and erlotinib for the treatment of solid tumors: a phase 1b study.

scientific article

Survival Impact of Adjuvant Chemotherapy for Resected Locally Advanced Rectal Adenocarcinoma

scientific article published on 6 October 2016

Survival impact of the Australian National Bowel Cancer Screening Programme.

scientific article

Survival in stage II/III colorectal cancer is independently predicted by chromosomal and microsatellite instability, but not by specific driver mutations

scientific article published on 17 September 2013

Systematic Review of Clinical Outcomes Following Various Treatment Options for Patients with Extraabdominal Desmoid Tumors

scientific article published on 11 April 2018

Systematic Screening Identifies Dual PI3K and mTOR Inhibition as a Conserved Therapeutic Vulnerability in Osteosarcoma

scientific article published on 10 April 2015

Targeting BRAF mutant metastatic colorectal cancer: clinical implications and emerging therapeutic strategies

scientific article published on 15 August 2014

The clinical KRAS(G12C) inhibitor AMG 510 drives anti-tumour immunity

scientific article published on 30 October 2019

The past, present, and future of cytotoxic chemotherapy and pathway-directed targeted agents for soft tissue sarcoma.

scientific article published on January 2013

The value of networks in driving phase I trials: the Peter MacCallum Cancer Centre experience

scientific article published on 01 June 2019

Thyrotoxicosis during sunitinib treatment for renal cell carcinoma.

scientific article published on 3 April 2008

Translation of clinical trial outcomes to metastatic colorectal cancer patients in community practice.

scientific article published on 17 August 2014

Treatment of patients with primary retroperitoneal sarcoma: predictors of outcome from an Australian specialist sarcoma centre

article

Variations of Surveillance Practice for Patients with Bone Sarcoma: A Survey of Australian Sarcoma Clinicians.

scientific article published on 28 February 2017

Wiki-based clinical practice guidelines for the management of adult onset sarcoma: a new paradigm in sarcoma evidence.

scientific article

Wild-type APC predicts poor prognosis in microsatellite-stable proximal colon cancer

scientific article

Wither surgical oncology?

scientific article published on 01 January 2019

List of works by Jayesh Desai

31st Annual Meeting and Associated Programs of the Society for Immunotherapy of Cancer (SITC 2016): part one

A First-Time-In-Human Phase I Clinical Trial of Bispecific Antibody-Targeted, Paclitaxel-Packaged Bacterial Minicells

A Phase Ib Dose-Escalation and Expansion Study of the BCL2 Inhibitor Venetoclax Combined with Tamoxifen in ER and BCL2-Positive Metastatic Breast Cancer

A multi-arm phase I dose escalating study of an oral NOTCH inhibitor BMS-986115 in patients with advanced solid tumours.

A mutant BRAF V600E-specific immunohistochemical assay: correlation with molecular mutation status and clinical outcome in colorectal cancer

A phase 1, first-in-human study of AMG 900, an orally administered pan-Aurora kinase inhibitor, in adult patients with advanced solid tumors

A phase I trial to determine safety and pharmacokinetics of ASLAN002, an oral MET superfamily kinase inhibitor, in patients with advanced or metastatic solid cancers.

A phase Ib/II translational study of sunitinib with neoadjuvant radiotherapy in soft-tissue sarcoma

An Australasian perspective on sarcoma research, translational biology and clinical trials: the Australasian Sarcoma Study Group (ASSG).

An initial watch and wait approach is a valid strategy for selected patients with newly diagnosed metastatic colorectal cancer.

Analysis of cellular phosphatidylinositol (3,4,5)-trisphosphate levels and distribution using confocal fluorescent microscopy

Analysis of local chronic inflammatory cell infiltrate combined with systemic inflammation improves prognostication in stage II colon cancer independent of standard clinicopathologic criteria

Antiangiogenic therapies targeting the vascular endothelia growth factor signaling system.

Binimetinib, Encorafenib, and Cetuximab Triplet Therapy for Patients With BRAF V600E-Mutant Metastatic Colorectal Cancer: Safety Lead-In Results From the Phase III BEACON Colorectal Cancer Study

Blood-based biomarkers of SU11248 activity and clinical outcome in patients with metastatic imatinib-resistant gastrointestinal stromal tumor.

CART-WHEEL.org: An Ethically Approved Online Database for Patient-Entered Data to Facilitate Rare Cancer Research

Cetuximab Alone or With Irinotecan for Resistant KRAS-, NRAS-, BRAF- and PIK3CA-wild-type Metastatic Colorectal Cancer: The AGITG Randomized Phase II ICECREAM Study

Circulating tumor DNA analysis detects minimal residual disease and predicts recurrence in patients with stage II colon cancer

Circulating tumor DNA as an early marker of therapeutic response in patients with metastatic colorectal cancer

Clinical, pharmacodynamic, and pharmacokinetic evaluation of BNC105P: a phase I trial of a novel vascular disrupting agent and inhibitor of cancer cell proliferation.

Clonal evolution of resistance to imatinib in patients with metastatic gastrointestinal stromal tumors

Comprehensive mapping of p53 pathway alterations reveals an apparent role for both SNP309 and MDM2 amplification in sarcomagenesis

Controversies in the management of gastrointestinal stromal tumors

Cost-effectiveness analysis of imaging surveillance in stage II and III extremity soft tissue sarcoma: an Australian perspective

Criteria-based curation of a therapy-focused compendium to support treatment recommendations in precision oncology

DNA copy-number alterations underlie gene expression differences between microsatellite stable and unstable colorectal cancers

Developing a national database for metastatic colorectal cancer management: perspectives and challenges.

Different APC genotypes in proximal and distal sporadic colorectal cancers suggest distinct WNT/β-catenin signalling thresholds for tumourigenesis.

Dose optimization of tyrosine kinase inhibitors to improve outcomes in GIST ⬇️

Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial

Encorafenib, Binimetinib, and Cetuximab in BRAF V600E-Mutated Colorectal Cancer

Examining the impact of regular aspirin use and PIK3CA mutations on survival in stage 2 colon cancer

Exploring the feasibility and utility of exome-scale tumour sequencing in a clinical setting

First-in-Man Dose-Escalation Study of the Selective BRAF Inhibitor RG7256 in Patients with BRAF V600-Mutated Advanced Solid Tumors.

First-in-human phase I clinical trial of a combined immune modulatory approach using TetMYB vaccine and Anti-PD-1 antibody in patients with advanced solid cancer including colorectal or adenoid cystic carcinoma: The MYPHISMO study protocol (NCT03287

Gemcitabine and vinorelbine combination chemotherapy for patients with advanced soft tissue sarcomas: results of a phase II trial.

Gender-specific activity of chemotherapy correlates with outcomes in chemosensitive cancers of young adulthood.

Girdin (GIV) Expression as a Prognostic Marker of Recurrence in Mismatch Repair-Proficient Stage II Colon Cancer

Histone deacetylase inhibitors in cancer: what have we learned?

Hypothyroidism after sunitinib treatment for patients with gastrointestinal stromal tumors.

ICECREAM: randomised phase II study of cetuximab alone or in combination with irinotecan in patients with metastatic colorectal cancer with either KRAS, NRAS, BRAF and PI3KCA wild type, or G13D mutated tumours

Immunomodulation by MYB is associated with tumor relapse in patients with early stage colorectal cancer.

Impact of BRAF mutation and microsatellite instability on the pattern of metastatic spread and prognosis in metastatic colorectal cancer

Impact of Diabetes Status and Medication on Presentation, Treatment, and Outcome of Stage II Colon Cancer Patients

Impact of Primary Tumor Site on Bevacizumab Efficacy in Metastatic Colorectal Cancer

Impact of body mass index on colorectal cancer treatment and outcomes: need for prospective and comprehensive data.

Impact of regular aspirin use on overall and cancer-specific survival in patients with colorectal cancer harboring a PIK3CA mutation

KRAS Mutation Is Associated with Lung Metastasis in Patients with Curatively Resected Colorectal Cancer

KRAS mutation testing of metastatic colorectal cancer in Australia: where are we at?

KRASG12C Inhibition with Sotorasib in Advanced Solid Tumors

Lack of clinical activity with crizotinib in a patient with FUS rearranged rhabdomyosarcoma with ALK protein overexpression

Long-term efficacy of imatinib mesylate in patients with advanced Tenosynovial Giant Cell Tumor

MACROD2 Haploinsufficiency Impairs Catalytic Activity of PARP1 and Promotes Chromosome Instability and Growth of Intestinal Tumors

Management of gastrointestinal stromal tumors in the era of tyrosine kinase inhibitors.

Mechanistic Insights of an Immunological Adverse Event Induced by an Anti-KIT Antibody Drug Conjugate and Mitigation Strategies

Metastasis-Associated Gene Expression Changes Predict Poor Outcomes in Patients with Dukes Stage B and C Colorectal Cancer

Microsatellite instability status is critical to analysis of survival in stage II colon cancer

Multicenter retrospective analysis of metastatic colorectal cancer (CRC) with high-level microsatellite instability (MSI-H).

Neurofibromatosis type 1-associated wild-type gastrointestinal stromal tumor treated with anti-IGF-1R monoclonal antibody.

Nivolumab for the treatment of colorectal cancer

Nivolumab in patients with metastatic DNA mismatch repair-deficient or microsatellite instability-high colorectal cancer (CheckMate 142): an open-label, multicentre, phase 2 study.

Novel Vaccine Targeting Colonic Adenoma: a Pre-clinical Model

Novel quality indicators for metastatic colorectal cancer management identify significant variations in these measures across treatment centers in Australia.

Nutlin-3a efficacy in sarcoma predicted by transcriptomic and epigenetic profiling

Optimising the management of soft tissue tumours ⬇️

Overview of biomarkers in metastatic colorectal cancer: tumour, blood and patient-related factors.

PIK3CA and PTEN gene and exon mutation-specific clinicopathologic and molecular associations in colorectal cancer

Pexidartinib versus placebo for advanced tenosynovial giant cell tumour (ENLIVEN): a randomised phase 3 trial

Phase I, Open-Label, Dose-Escalation/Dose-Expansion Study of Lifirafenib (BGB-283), an RAF Family Kinase Inhibitor, in Patients With Solid Tumors

Phase II study of ganitumab, a fully human anti-type-1 insulin-like growth factor receptor antibody, in patients with metastatic Ewing family tumors or desmoplastic small round cell tumors

Phase Ib study of atezolizumab combined with cobimetinib in patients with solid tumors

Precision oncology using a clinician-directed, tailored approach to molecular profiling.

Primary Tumor Resection in Patients With Metastatic Colorectal Cancer Is Associated With Reversal of Systemic Inflammation and Improved Survival.

Profound MEK inhibitor response in a cutaneous melanoma harboring a GOLGA4-RAF1 fusion

Re: Residual treatment disparities after oncology referral for rectal cancer

Recurrent SPECC1L-NTRK fusions in paediatric sarcoma and brain tumours

Resistance to BRAF Inhibition in BRAF-Mutant Colon Cancer Can Be Overcome with PI3K Inhibition or Demethylating Agents ⬇️

Response assessment in gastrointestinal stromal tumor.

Response to "Disparities in the use of chemotherapy and monoclonal antibody therapy for elderly advanced colorectal cancer patients in the community oncology setting".